The endocannabinoid system (ECS) is a biological signaling network found in all vertebrates that regulates mood, memory, pain, appetite, sleep, immune function, and homeostasis. It consists of three components: endocannabinoids (naturally produced cannabinoid-like molecules in the body), cannabinoid receptors (CB1 and CB2), and enzymes that synthesize and break down endocannabinoids. The ECS was discovered in the 1990s as a result of research into how THC produces its effects — researchers discovered the receptors THC was binding to, then worked backward to find the body's own natural ligands: anandamide (the “bliss molecule”) and 2-AG.

What are CB1 and CB2 receptors?

CB1 receptors are found predominantly in the brain and central nervous system — particularly in the cerebral cortex, hippocampus, basal ganglia, and cerebellum. CB1 activation produces most of cannabis's psychoactive effects: euphoria, altered memory, impaired coordination, and appetite stimulation. CB2 receptors are found primarily in immune cells and peripheral tissues. CB2 activation modulates immune function and inflammation without psychoactivity. THC activates both CB1 and CB2. CBD primarily acts as an indirect ECS modulator — it inhibits the enzyme (FAAH) that breaks down anandamide, allowing the body's own endocannabinoids to accumulate and produce effects, rather than directly activating receptors.

What is anandamide and why does it matter?

Anandamide (AEA, from the Sanskrit “ananda” meaning bliss) is the body's primary endogenous cannabinoid — a naturally produced compound that binds CB1 and CB2 receptors. It's involved in reward, motivation, pain regulation, and short-term memory. The “runner's high” was traditionally attributed to endorphins but is now thought to be primarily driven by anandamide and endocannabinoid release during aerobic exercise. THC mimics anandamide at CB1 and CB2 but is far more potent and longer-lasting because it isn't broken down by FAAH quickly. CBD increases anandamide levels by blocking FAAH, which may explain CBD's anxiety-reducing and mood-stabilizing effects.

How do hemp products interact with the ECS?

Different hemp cannabinoids interact with the ECS in distinct ways. Delta-9 and Delta-8 THC: direct CB1 partial agonists (psychoactive). THCA: minimal direct CB1 binding until decarboxylated to THC. CBD: FAAH inhibition (raises anandamide), 5-HT1A serotonin agonism, TRPV1 antagonism, PPARgamma agonism — a multi-target modulator without direct CB1 activation. CBG: CB1 partial agonist plus GABA reuptake inhibition. THCP: very high CB1 binding affinity (33x THC). Understanding these interactions helps explain why different hemp products at Elevated Haze produce such different effects despite all being classified as “hemp cannabinoids.”

Can you have an endocannabinoid deficiency?

Clinical Endocannabinoid Deficiency (CECD) is a hypothesis proposed by researcher Ethan Russo suggesting that low endocannabinoid tone (insufficient natural cannabinoid signaling) may underlie conditions like migraine, fibromyalgia, and irritable bowel syndrome — all of which respond to cannabinoid treatment but have no clearly identified underlying cause. The CECD hypothesis is not yet established clinical doctrine but has generated significant research interest. Evidence supporting it: patients with these conditions often have lower CSF levels of anandamide; cannabis treatment has documented efficacy for all three conditions; and conditions known to reduce ECS activity (chronic stress, poor sleep) are risk factors for these syndromes.